Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

Market Cap	6.23M -18.2%
Revenue (ttm)	1.82M +10.9%
Net Income	-6.41M
EPS	n/a
Shares Out	19.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,229
Open	0.3300
Previous Close	0.3200
Day's Range	0.3040 - 0.3300
52-Week Range	0.2000 - 0.9200
Beta	-0.65
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALOPM

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 23, 2026

Data Sources Report a data error